Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.

Trial Details

NCT ID
NCT06621563
Phase
PHASE1
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HS-20117 combined HS-20093
  • HS-20117 combined Platinum-containing chemotherapy
  • HS-20117 combined HS-20093 and 5-FU
  • HS-20117+CAPEOX
  • HS-20117+FOLFIRI
  • HS-20117+mFOLFOX6
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Males or females aged 18 - 75 years (inclusive).
  • Histologically confirmed unresectable, recurrent or metastatic solid tumors.
  • At least one target lesion per the RECIST v1.1.
  • ECOG performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →